KR20190040936A - 파르네소이드 x 수용체 (fxr) 조정제와의 조합 요법 - Google Patents

파르네소이드 x 수용체 (fxr) 조정제와의 조합 요법 Download PDF

Info

Publication number
KR20190040936A
KR20190040936A KR1020187037471A KR20187037471A KR20190040936A KR 20190040936 A KR20190040936 A KR 20190040936A KR 1020187037471 A KR1020187037471 A KR 1020187037471A KR 20187037471 A KR20187037471 A KR 20187037471A KR 20190040936 A KR20190040936 A KR 20190040936A
Authority
KR
South Korea
Prior art keywords
optionally substituted
group
heteroaryl
alkyl
alkylene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020187037471A
Other languages
English (en)
Korean (ko)
Inventor
라주 모한
벤자민 앤토니 프라트
Original Assignee
아카나 테라퓨틱스, 엘티디.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아카나 테라퓨틱스, 엘티디. filed Critical 아카나 테라퓨틱스, 엘티디.
Publication of KR20190040936A publication Critical patent/KR20190040936A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020187037471A 2016-05-25 2017-05-25 파르네소이드 x 수용체 (fxr) 조정제와의 조합 요법 Ceased KR20190040936A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662341487P 2016-05-25 2016-05-25
US201662341482P 2016-05-25 2016-05-25
US62/341,487 2016-05-25
US62/341,482 2016-05-25
PCT/US2017/034564 WO2017205684A1 (en) 2016-05-25 2017-05-25 Combination therapies with farnesoid x receptor (fxr) modulators

Publications (1)

Publication Number Publication Date
KR20190040936A true KR20190040936A (ko) 2019-04-19

Family

ID=60412964

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020187037471A Ceased KR20190040936A (ko) 2016-05-25 2017-05-25 파르네소이드 x 수용체 (fxr) 조정제와의 조합 요법

Country Status (13)

Country Link
US (1) US20200397798A1 (https=)
EP (1) EP3463373A4 (https=)
JP (1) JP2019517478A (https=)
KR (1) KR20190040936A (https=)
CN (1) CN109843298A (https=)
AU (1) AU2017270221A1 (https=)
BR (1) BR112018073460A2 (https=)
CA (1) CA3025007A1 (https=)
IL (1) IL263179A (https=)
MX (1) MX2018014024A (https=)
RU (1) RU2018145776A (https=)
SG (2) SG10202011660RA (https=)
WO (1) WO2017205684A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021182876A1 (ko) * 2020-03-11 2021-09-16 동아에스티 주식회사 비알콜성지방간염의 예방 또는 치료를 위한 약학적 조성물

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2019144064A (ru) * 2017-06-02 2021-07-13 Акарна Терапьютикс, Лтд. Конденсированные бициклические соединения
US11590161B2 (en) 2018-08-13 2023-02-28 Viscera Labs, Inc. Therapeutic composition and methods
US11524029B2 (en) 2018-08-13 2022-12-13 Viscera Labs, Inc. Therapeutic composition and methods
JP2022514731A (ja) * 2018-08-14 2022-02-15 アヴォリント 原発性硬化性胆管炎の処置方法
US20210393662A1 (en) * 2018-10-18 2021-12-23 Avolynt Use of sglt2 inhibitors to treat primary sclerosing cholangitis
CN111320609A (zh) 2018-12-13 2020-06-23 拓臻股份有限公司 一种THRβ受体激动剂化合物及其制备方法和用途
CN111825653A (zh) * 2019-04-19 2020-10-27 安道麦马克西姆有限公司 取代吡唑类化合物的制备及其作为邻氨基苯甲酰胺前体的用途
AU2020336272A1 (en) 2019-08-23 2022-04-14 Terns Pharmaceuticals, Inc. Thyroid hormone receptor beta agonist compounds
WO2021050945A1 (en) 2019-09-12 2021-03-18 Terns, Inc. Thyroid hormone receptor beta agonist compounds
CN114929214A (zh) * 2019-11-22 2022-08-19 阿沃林特有限公司 Sglt2抑制剂治疗原发性胆汁性胆管炎的用途
US11478533B2 (en) 2020-04-27 2022-10-25 Novo Nordisk A/S Semaglutide for use in medicine
US20220034871A1 (en) * 2020-07-31 2022-02-03 Daiichi Sankyo Company, Limited Methods for administering pexidartinib
CA3193057A1 (en) 2020-08-25 2022-03-03 Eli Lilly And Company Polymorphs of an ssao inhibitor
US20240319210A1 (en) * 2020-12-18 2024-09-26 Human Metabolomics Institute, Inc. Application of neonatal biliary atresia biomarker and detection method for same

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8466143B2 (en) * 2003-07-23 2013-06-18 Exelixis, Inc. Azepine derivatives as pharmaceutical agents
JP5081161B2 (ja) * 2005-12-19 2012-11-21 スミスクライン ビーチャム コーポレーション ファルネソイドｘ受容体アゴニスト
ES2552657T3 (es) * 2010-05-26 2015-12-01 Satiogen Pharmaceuticals, Inc. Inhibidores del reciclado de ácidos biliares y saciógenos para el tratamiento de diabetes, obesidad, y afecciones gastrointestinales inflamatorias
EP3777863A1 (en) * 2014-09-12 2021-02-17 Tobira Therapeutics, Inc. Cenicriviroc combination therapy for the treatment of fibrosis
CN111662297A (zh) * 2014-11-21 2020-09-15 阿卡纳治疗学有限公司 用于治疗疾病的稠合双环化合物
EP3715348A1 (en) * 2015-03-26 2020-09-30 Akarna Therapeutics, Ltd. Fused bicyclic compounds for the treatment of disease

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021182876A1 (ko) * 2020-03-11 2021-09-16 동아에스티 주식회사 비알콜성지방간염의 예방 또는 치료를 위한 약학적 조성물
AU2021235832B2 (en) * 2020-03-11 2024-02-29 Dong-A St Co., Ltd. Pharmaceutical composition for prevention or treatment of nonalcoholic steatohepatitis

Also Published As

Publication number Publication date
RU2018145776A (ru) 2020-06-26
WO2017205684A1 (en) 2017-11-30
SG10202011660RA (en) 2020-12-30
RU2018145776A3 (https=) 2021-03-01
EP3463373A4 (en) 2020-04-22
SG11201810290WA (en) 2018-12-28
CA3025007A1 (en) 2017-11-30
AU2017270221A1 (en) 2018-12-20
BR112018073460A2 (pt) 2019-07-09
IL263179A (en) 2018-12-31
CN109843298A (zh) 2019-06-04
US20200397798A1 (en) 2020-12-24
MX2018014024A (es) 2019-08-29
EP3463373A1 (en) 2019-04-10
JP2019517478A (ja) 2019-06-24

Similar Documents

Publication Publication Date Title
KR20190040936A (ko) 파르네소이드 x 수용체 (fxr) 조정제와의 조합 요법
JP5411141B2 (ja) 細胞内カルシウムを調節する化合物
EP2086538B1 (en) Combination therapies for treating alzheimer's disease using dimebon and donepezil
TW202517269A (zh) 治療克羅恩氏病和潰瘍性結腸炎之方法
JP2018532720A (ja) 線維症の治療のためのセニクリビロック併用療法
US12396989B2 (en) Nicorandil derivatives
JP7656548B2 (ja) 痛風または高尿酸血症を処置するための化合物
JP2023510604A (ja) 再発型多発性硬化症（ｒｍｓ）用の治療用チロシンキナーゼ阻害剤
CN113164439A (zh) 用于治疗或预防痛风或高尿酸血症的方法
TW200803851A (en) Pharmaceutical composition for improvement of cognitive function
RU2727142C2 (ru) Бисамидное производное дикарбоновой кислоты в качестве средства, стимулирующего регенерацию тканей и восстановление сниженных функций тканей
US11000481B2 (en) Composite preparation of mosapride and rabeprazole
JP2025524598A (ja) Ｓ１ｐ受容体モジュレーターの結晶形態
KR20230074132A (ko) Olig2 억제제를 사용하는 조합 요법
US20210346366A1 (en) Ch24h inhibitors for pain use
EP3923932A1 (en) Treatment for polycystic ovarian syndrome (pcos)
CN120435291A (zh) 用于多发性硬化的治疗性酪氨酸激酶抑制剂
WO2024231312A2 (en) Combination therapy
JP2008195625A (ja) Ｇ蛋白質共役型レセプター抑制剤および医薬
HK40056575A (en) Methods for treating or preventing gout or hyperuricemia

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20181224

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200518

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20220210

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20220526

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20220210

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I